Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
November 08 2018 - 10:30AM
Press Release
8 November 2018
Report from Extraordinary General Meeting of Immunicum AB (publ) on
8 November 2018
The Extraordinary
General Meeting (the "EGM") of Immunicum AB (publ), reg. no
556629-1786, was held today. The EGM resolved to approve both the
Board of Directors' resolution on a directed share issue and to
approve the Board of Directors' resolution on a new issue of shares
with preferential rights for the shareholders. For more detailed
information regarding the contents of the resolutions, refer to the
complete proposals, which have previously been published and are
available on the company's website, www.immunicum.com.
Resolution on
approval of directed new issue of shares
The EGM resolved to approve the
Board of Directors' resolution of 16 October 2018 on a new issue of
shares with deviation from the shareholders' preferential
rights.
The directed issue entails that
the company's share capital shall be increased with a maximum
amount of SEK 1,045,779.40 by issue of at most 20,915,588 new
shares. The subscription price is SEK 8.50 per share and is deemed
to be in accordance with the market. At full subscription the
company will be provided with an amount of approximately MSEK 178
(before issue expenses).
Resolution on
approval of new issue of shares (rights issue)
The EGM resolved to approve the
Board of Directors' resolution of 16 October 2018 on a new issue of
shares with preferential rights for the shareholders.
The Rights Issue entails that the
company's share capital shall be increased with a maximum amount of
1,019,170.60 SEK by issue of at most 20,383,412 new shares with
preferential rights for the company's existing shareholders. The
subscription price is SEK 8.50 per share. At full subscription the
company will be provided with an amount of approximately MSEK 173
(before issue expenses).
Shareholders in the company have
preferential right to subscribe for shares whereupon one (1)
existing share in the company entitles to one (1) subscription
right and five (5) subscription rights entitle to subscribe for two
(2) new shares. New shares may also be subscribed for without
subscription rights.
The record date for obtaining
subscription rights and the right to participate in the new issue
of shares with preferential rights is on Wednesday, 21 November
2018. Subscription of shares, both with and without the exercise of
subscription rights, is to take place during the period starting on
Monday, 26 November 2018 up to and including Monday, 10 December
2018.
The information in
this press release is disclosed pursuant to the rules for companies
listed on Nasdaq Stockholm. The information was released for public
disclosure through the agency of the company's contact person on 8
November, 2018 at 4.30 pm CET.
For more information, please contact:
Carlos de Sousa, CEO,
Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Michaela Gertz, CFO,
Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com
Media Relations
Gretchen Schweitzer and Joanne
Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com
About Immunicum AB (publ) Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm. www.immunicum.com
|
20181108_Immunicum Report From
EGM_ENG_FINAL
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024